Investment Thesis — Regeneron Pharmaceuticals, Inc.
The market underestimates Regeneron's ability to compound earnings through pipeline innovation and strategic partnerships, mispricing its future cash flows due to a narrow focus on current product revenues. Investors are anchored to legacy drugs and overlook the company's accelerating biologics platform and next-gen immunology assets.
Catalysts
- Positive late-stage trial results for immunology assets
- New strategic partnership announcements
- Accelerated FDA approvals for pipeline drugs
Risk Factors
- Pipeline clinical failures
- Competitive biologics pricing pressure
- Regulatory or reimbursement setbacks
Key Debates
REGN's 16.93x P/E expands to 20x by Q4
REGN exceeds 858.28 analyst target by Q3
Short float rises above 3.5% by H2 on growth concerns